WebMay 16, 2013 · With the rivalry between Thoratec and HeartWare intensifying in the LVAD space, all eyes are now on recent strategic acquisitions by both companies, as well as ongoing clinical studies and next-generation devices in the pipeline. HeartWare Adds Synergy Circulatory Support System With $30 Mil. CircuLite Buy. The acquisition could … WebSep 6, 2012 · CircuLite has obtained CE mark for its new micro-blood pump Synergy Circulatory Support system, designed to treat ambulatory heart failure patients (INTERMACS 4,5,6 / NYHA IIIB and early IV). The Synergy system, which is implanted using a mini-thoracotomy, is placed in a pacemaker-like pocket under the right …
CircuLite® Presents Positive Hemodynamic, Exercise Tolerance …
WebMar 7, 2014 · Synergy ® CircuLite ® micropump is an AA battery size partial support VAD which can be implanted without cardiopulmonary bypass (CPB) or sternotomy . The system is surgically implanted through a mini-thoracotomy and the micropump is placed in a pacemaker-like pocket [2, 3]. Unlike conventional full support ventricular-assist devices, … WebMay 15, 2013 · IC System Specifically Designed for Interventional Cardiologist Cannula Deployment. TEANECK, NJ – CircuLite®, Inc. today announced that it has received approval from the Federal Agency for Medicines and Health Products in Belgium to commence the CE Mark trial of the SYNERGY® IC Circulatory Support System, the first … how many racehorses die each year in uk
CircuLite new micro-blood pump system wins CE mark
WebMar 5, 2013 · CircuLite®, Inc. has today announced receipt of conditional approval from the U.S. FDA of an Investigational Device Exemption (IDE) for its lead product, the SYNERGY® Circulatory Support System. Synergy is a minimally-invasive device designed to reverse the symptoms of heart failure in ambulatory chronic heart failure patients. WebSep 10, 2012 · Company Recently Announced European CE Mark Approval for SYNERGY CircuLite®, Inc. today announced that the latest data from patients enrolled in the Company’s CE Mark trial of the SYNERGY® Circulatory Support System were presented on Monday, September 10 in a WebHeartWare has cash and equivalents of $187.91 million against a long-term debt of $105.34 million as of the third quarter of 2013, but the company is not profitable yet. I believe that … how deep do carrots need to grow